Dr Gnant - ESMO Oral Presentation 08
Dr Gnant - ESMO Oral Presentation 08
Dr Gnant - ESMO Oral Presentation 08
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
ZOL Reduced Recurrence at All Sites<br />
First event per patient, n<br />
90<br />
80<br />
70<br />
60<br />
50<br />
40<br />
30<br />
20<br />
10<br />
0<br />
2<br />
10<br />
10<br />
41<br />
20<br />
No ZOL vs ZOL<br />
No ZOL ZOL<br />
(n = 904) (n = 899)<br />
DFS = Disease-free survival; ITT = Intent-to-treat; ZOL = Zoledronic acid.<br />
<strong>Gnant</strong> M, et al. Presented at: ASCO 20<strong>08</strong>. Chicago, IL. Abstract LBA4.<br />
0<br />
9<br />
6<br />
29<br />
10<br />
Death without prior recurrence<br />
Secondary malignancy<br />
Contralateral breast cancer<br />
Distant recurrence<br />
Locoregional recurrence<br />
14
Change language